AbbVie

AbbVie (NYSE:ABBV) today announced a $1.4 billion investment to build a new pharmaceutical manufacturing campus in Durham, North Carolina. The 185-acre, state-of-the-art campus will integrate advanced manufacturing and laboratory technologies with AI to support the production of AbbVie’s immunology, neuroscience and oncology medicine. It marks the latest significant investment in pharmaceutical manufacturing after the company…

AbbVie (NYSE:ABBV) today announced plans to invest $380 million in two new active pharmaceutical ingredient (API) manufacturing facilities. The investment comes at the company’s current North Chicago, Illinois, campus. With it, the company plans to add new, state-of-the-art facilities to integrate advanced manufacturing technologies with AI to support the production of its next-generation neuroscience and…

AbbVie (NYSE: ABBV) recently announced that it has acquired a West Pharmaceutical Services (NYSE: WST) plant in Tempe, Arizona. North Chicago, Illinois–based AbbVie said on Jan. 12 that it plans to hire roughly 200 employees at the site and invest more than $175 million to acquire, modernize, and fully integrate the facility into its manufacturing…

AbbVie (NYSE:ABBV) announced that it began construction for a $70 million expansion of its bioresearch center (ABC) in Worcester, Massachusetts. The ABC in Worcester serves as a center of excellence for biologics R&D and manufacturing. AbbVie said its latest expansion comes as part of a plan to invest more than $10 billion in the U.S.…

AbbVie (NYSE:ABBV) announced today that it invested $195 million to expand domestic active pharmaceutical ingredient (API) production. The company’s investment comes in its North Chicago, Illinois, plant to advance its U.S. API manufacturing. This expansion comes as part of AbbVie’s commitment to invest more than $10 billion in the U.S. to broadly support innovation and…

AbbVie (NYSE: ABBV) recently announced that its board of directors has decided to promote the company’s president and COO Robert A. Michael into the corner office. Michael will succeed Richard A. Gonzalez, who is retiring as CEO on July 1. Gonzalez will stay as executive chair of AbbVie’s board. “On behalf of AbbVie’s board, I…

AbbVie (NYSE: ABBV) recently announced that it will spend $223 million to expand its Singapore biologics manufacturing facility. Construction will commence immediately, with the facilities coming online in 2026. The added facilities will create 100 new jobs at the plant, boosting total employment to more than 500 positions in manufacturing, quality assurance, supply chain, engineering…

AbbVie (NYSE: ABBV) recently announced the launch of its Parkinson’s disease drug Produodopa (foslevodopa/foscarbidopa) in the European Union. Produodopa is for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement). It’s indicated for use when combinations of Parkinson’s medicinal products have not given satisfactory results. North…

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and AbbVie unit Allergan Plc (NYSE:ABBV) could pay more than $5 billion in total to settle some 3,500 opioid lawsuits, according to Bloomberg. While the two companies are willing to settle the suits in the consolidated case, the deal has not been finalized. The consolidated case is titled In Re National…

AbbVie (NYSE:ABBV) shares ticked up before hours today on third-quarter results that beat the consensus forecast. The North Chicago, Illinois-based company posted profits of $3.2 billion, or $1.78 per share, on sales of $14.34 billion for the three months ended Sept. 30, 2021, for a 37.5% bottom-line gain on sales growth of 11.2%. Adjusted to…